Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Nengwen Ke

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7135-2244; OpenAlex author ID A5029458909, A5055328740. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: 4 papers · 2024: 3 papers · 2025: 2 papers · 2026: 1 paper

Papers 22

  1. Targeted inhibition of HK2 expression in pancreatic ductal adenocarcinoma reprogrammes the immune microenvironment by regulating CCL5-mediated CD8+ T cell infi… Last author DOI 10.1016/j.intimp.2026.117602↗
  2. 64Cu Radiolabeled PDGFRβ-Targeting Affibody for PET Imaging in Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.4c01368↗
  3. The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-1712↗
  4. TIM-4 increases the proportion of CD4+CD25+FOXP3+ regulatory T cells in the pancreatic ductal adenocarcinoma microenvironment by inhibiting IL-6 secretion. Last author DOI 10.1002/cam4.70110↗
  5. Preoperative metabolic syndrome and prognosis after pancreatectomy for pancreatic cancer: A retrospective study. Last author DOI 10.1002/wjs.12263↗
  6. Case report: Achieving significant tumor reduction in advanced pancreatic adenocarcinoma. Last author DOI 10.3389/fonc.2024.1458517↗
  7. The differential effects of sarcopenia and cachexia on overall survival for pancreatic ductal adenocarcinoma patients following pancreatectomy: A retrospective… Last author DOI 10.1002/cam4.5779↗
  8. Copper deprivation enhances the chemosensitivity of pancreatic cancer to rapamycin by mTORC1/2 inhibition. First author DOI 10.1016/j.cbi.2023.110546↗
  9. Prognostic role of radiological splenic vessel involvement in patients with resectable pancreatic ductal adenocarcinoma of the body and tail: A retrospective a… Last author DOI 10.1016/j.ejrad.2023.110952↗
  10. Long Term Outcomes of No-Touch Isolation Principles Applied in Pancreaticoduodenectomy for Treatment of Pancreatic Adenocarcinoma: A Multicenter Retrospective … Last author DOI 10.3390/jcm12020632↗
  11. Comment on: Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationwide coho… Last author DOI 10.1093/bjs/znac058↗
  12. The expression of m6A regulators correlated with the immune microenvironment plays an important role in the prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/gs-21-859↗
  13. Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: … Last author DOI 10.3389/fonc.2021.801320↗
  14. MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-020-1146-x↗
  15. [Inhibition of Copper Transporter-1 by Ammonium Tetrathiocarbolybdate in the Treatment of Pancreatic Cancer]. Co-author DOI 10.12182/20200960101↗
  16. Assessment of Standardization Circumferential Resection Margin Status Influence Survival following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma Last author DOI 10.21203/rs.3.rs-113904/v1↗
  17. Risk of pancreatic cancer in patients undergoing surgery for chronic pancreatitis. Co-author DOI 10.1186/s12893-019-0537-1↗
  18. A case-matched comparison study of total pancreatectomy versus pancreaticoduodenectomy for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ijsu.2017.10.065↗
  19. MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy. Co-author DOI 10.18632/oncotarget.22494↗
  20. dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Stud… Co-author DOI 10.1097/md.0000000000002936↗
  21. [Viability of extended distal pancreatectomy for pancreatic adenocarcinoma of the body or tail]. Co-author DOI 10.3760/cma.j.issn.0529-5815.2016.03.010↗
  22. [The expressions and correlation of bcl-2 and Beclin-1 in pancreatic cancer]. Co-author PMID 22650021↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xubao Liu · 9 shared papers, 2016–2023 · strength 1.35
  2. Ziyao Wang · 6 shared papers, 2021–2024 · strength 1.33
  3. Ruiman Geng · 4 shared papers, 2020–2025 · strength 0.75
  4. Qingquan Tan · 3 shared papers, 2020–2026 · strength 0.67
  5. Chunlu Tan · 5 shared papers, 2016–2023 · strength 0.65
  6. Yu Mou · 3 shared papers, 2023–2024 · strength 0.60
  7. Xiaoding Shen · 2 shared papers, 2023–2024 · strength 0.48
  8. Xing Wang · 2 shared papers, 2022–2023 · strength 0.47
  9. Huawei Cai · 2 shared papers, 2023–2025 · strength 0.38
  10. Yonghua Chen · 2 shared papers, 2022–2023 · strength 0.37
  11. Junjie Xiong · 4 shared papers, 2016–2022 · strength 0.36
  12. Minglin Li · 1 shared paper, 2026 · strength 0.33
  13. Zhenjiang Zheng · 2 shared papers, 2019–2023 · strength 0.32
  14. Hongying Liu · 1 shared paper, 2024 · strength 0.31
  15. Qian Zhang · 1 shared paper, 2024 · strength 0.31
  16. Fenglin Gu · 1 shared paper, 2024 · strength 0.28
  17. Xu-Bao Liu · 2 shared papers, 2020 · strength 0.28
  18. Ji Liu · 2 shared papers, 2020–2023 · strength 0.26
  19. Ruomeng Liu · 1 shared paper, 2025 · strength 0.24
  20. Li Zhao · 1 shared paper, 2025 · strength 0.24
  21. Haoqi Zhang · 1 shared paper, 2023 · strength 0.22
  22. Wenyan Xie · 1 shared paper, 2025 · strength 0.20
  23. Jie Yang · 1 shared paper, 2025 · strength 0.20
  24. Hong Jiang · 1 shared paper, 2025 · strength 0.20
  25. Yunhua Liu · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.